Stockscreener 앱 받기
60.32
3.20%
1.81
전일 마감가:
$58.51
열려 있는:
$58.42
하루 거래량:
438.20K
Relative Volume:
0.32
시가총액:
$8.67B
수익:
-
순이익/손실:
$-507.65M
주가수익비율:
-13.11
EPS:
-4.6
순현금흐름:
$-616.24M
1주 성능:
+11.61%
1개월 성능:
+14.51%
6개월 성능:
+86.99%
1년 성능:
-24.28%
1일 변동 폭
$58.16
$61.25
1주일 범위
$52.86
$61.25
52주 변동 폭
$27.66
$83.33
백스사이트 Stock (PCVX) Company Profile
명칭
Vaxcyte Inc
전화
650-837-0111
주소
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
60.37 | 8.40B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.83 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
788.50 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
835.15 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.60 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
366.96 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
백스사이트 Stock (PCVX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재확인 | Needham | Buy |
| 2025-09-12 | 개시 | Goldman | Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-20 | 개시 | Goldman | Buy |
| 2023-12-07 | 개시 | Mizuho | Buy |
| 2023-04-18 | 개시 | TD Cowen | Outperform |
| 2023-01-03 | 재확인 | Needham | Buy |
| 2022-12-15 | 개시 | Guggenheim | Buy |
| 2022-11-17 | 개시 | BTIG Research | Buy |
| 2021-12-29 | 재개 | Jefferies | Buy |
| 2021-06-24 | 재개 | Jefferies | Buy |
| 2020-07-07 | 개시 | BofA Securities | Buy |
| 2020-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-07-07 | 개시 | Needham | Buy |
모두보기
백스사이트 주식(PCVX)의 최신 뉴스
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring a 74% Potential Upside in the Innovative Vaccine Sector - DirectorsTalk Interviews
Earnings Outlook For Vaxcyte - Benzinga
Aug Movers: Whats the RSI of Vaxcyte Inc stockRisk Management & Safe Entry Trade Signal Reports - baoquankhu1.vn
Volume Report: Is Vaxcyte Inc affected by consumer sentiment2025 Earnings Surprises & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Aug Retail: What hedge funds are buying MFS High Yield Municipal TrustDividend Hike & AI Powered Market Trend Analysis - baoquankhu1.vn
Technical Analysis: Is PSMT a defensive stockPrice Action & Daily Volume Surge Signals - baoquankhu1.vn
Vaxcyte’s VAX-31 Moves Into Phase 3: What This Pneumococcal Vaccine Update Means for PCVX Investors - TipRanks
Vaxcyte shows market leadership with jump to 85 RS rating - MSN
Vaxcyte Inc. (PCVX) Confident of Topline Data in Pneumococcal Vaccine Trials - Finviz
Vaxcyte (PCVX) $632.5M stock offering follows bullish Cantor Fitzgerald rating - MSN
Vaxcyte (PCVX) $632.5M Stock Offering Follows Bullish Cantor Fitzgerald Rating - Finviz
Vaxcyte (PCVX) price target increased by 19.72% to 99.96 - MSN
Impressive Clinical Pipeline Leads to Bullish Sentiment for Vaxcyte (PCVX) - Bitget
Should Vaxcyte’s OPUS-3 Phase 3 VAX-31 Trial Milestone Require Action From Vaxcyte (PCVX) Investors? - Yahoo Finance
Precision Trading with Vaxcyte Inc. (PCVX) Risk Zones - Stock Traders Daily
Nasdaq Moves: What is the target price for Vaxcyte Inc. stockEarnings Overview Summary & Verified Short-Term Plans - mfd.ru
Vaxcyte Spotlights VAX-31 Phase 3 Launch, Eyes Adult BLA by End of Next Year at Biotech Summit - MarketBeat
Is now the right time to enter Vaxcyte Inc.Market Activity Report & Safe Capital Growth Tips - mfd.ru
Vaxcyte (PCVX) Initiates Phase 3 Trial for VAX-31 Vaccine in Adu - GuruFocus
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines - The Manila Times
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial - GlobeNewswire
Vaxcyte, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 - Quiver Quantitative
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 - marketscreener.com
Vaxcyte to Report Fourth Quarter and Full Year 2025 - GlobeNewswire
IPO Launch: What is the target price for Vaxcyte Inc stockMarket Risk Report & Safe Swing Trade Setups - baoquankhu1.vn
Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Vaxcyte, Inc. $PCVX Shares Bought by Federated Hermes Inc. - MarketBeat
How Investors May Respond To Vaxcyte (PCVX) Raising $550 Million To Fund Pneumococcal Vaccine Pipeline - Sahm
Aug Wrap: Does Stepan Company have consistent dividend growth2025 AllTime Highs & Fast Gain Swing Alerts - baoquankhu1.vn
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit - 富途牛牛
Commit To Buy Vaxcyte At $45, Earn 19.3% Annualized Using Options - Nasdaq
Technical Reactions to PCVX Trends in Macro Strategies - Stock Traders Daily
Vaxcyte closes $632.5 million public offering of common stock By Investing.com - Investing.com India
Vaxcyte Completes Public Equity Offering, Bolstering Capital Position - The Globe and Mail
Is It Time To Reassess Vaxcyte (PCVX) After Recent Share Price Recovery - Yahoo Finance
Assessing Vaxcyte (PCVX) Valuation After Recent Share Price Momentum - Yahoo Finance
Vaxcyte Funding And Late-Stage Trials Put Valuation In Focus - Yahoo Finance
Vaxcyte (NASDAQ:PCVX) Stock Price Up 8.1%Time to Buy? - MarketBeat
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring A Potential 90.61% Upside For Investors - DirectorsTalk Interviews
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Investing News Network
Vaxcyte Closes Public Offering of Shares - marketscreener.com
Vaxcyte closes $632.5 million public offering of common stock - Investing.com
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Vaxcyte, Inc. Completes $632.5 Million Public Offering of Common Stock - Quiver Quantitative
백스사이트 (PCVX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.88%
0.77%
자본화:
|
볼륨(24시간):